COVID-19 and the neurological disease therapeutic pipeline

Gregory A Jicha; Erin L Abner

doi:10.1038/s41582-020-00445-w

COVID-19 and the neurological disease therapeutic pipeline

Nat Rev Neurol. 2021 Feb;17(2):71-72. doi: 10.1038/s41582-020-00445-w.

Authors

Gregory A Jicha^{1

2}, Erin L Abner^{3

4}

Affiliations

¹ Department of Neurology, University of Kentucky College of Medicine, Lexington, KY, US. gajich2@email.uky.edu.
² The Sanders-Brown Center on Aging, University of Kentucky College of Medicine, Lexington, KY, US. gajich2@email.uky.edu.
³ The Sanders-Brown Center on Aging, University of Kentucky College of Medicine, Lexington, KY, US.
⁴ Department of Epidemiology, University of Kentucky College of Public Health, Lexington, KY, US.

Abstract

From the interruption of clinical trials by shelter-in-place orders to the challenges involved in safely collecting biofluid samples, drug development for neurological disease was hit hard by the COVID-19 pandemic this year. However, the field has responded with innovative solutions, and 2021 could see the therapeutic pipeline flowing again.

Publication types

Review

MeSH terms

COVID-19 / epidemiology
COVID-19 / prevention & control*
COVID-19 / transmission
Clinical Trials as Topic / organization & administration*
Communicable Disease Control / organization & administration*
Drug Development / organization & administration*
Humans
Nervous System Diseases / drug therapy*